Nektar Therapeutics (NKTR) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $59.31 -2.72%
Revenue Growth %: -11.4%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -11.4%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.32), $0.04 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $36.3 million versus the consensus estimate of $32.42 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
- Espey Manufacturing (ESP) Tops Q4 EPS by 24c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
